Drug major Lupin Ltd today said it has entered into a licensing pact for various patents of cholesterol lowering drug 'Antara' capsules with US-based Abbott Laboratories and France's Laboratoires Fournier SA.
Lupin and its subsidiaries Lupin Pharmaceuticals Inc and Lupin Atlantis Holding SA, have entered into a licence agreement with Abbott Laboratories and Laboratoires Fournier SA for various Abbott patents for Antara (Fenofibrate) capsules, the company said in a statement.
The company did not disclose details of the patent licensing agreement citing confidentiality.
The agreement covers as many as eight patents in the US for the drug besides any divisionals, continuations, continuations in part, reissues, re-examinations, and extensions, it added.
Shares of Lupin today closed at Rs 419.20 on the Bombay Stock Exchange, up 1.09% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app